@article{ec805cd026574b0db396a5eed35e1e5e,
title = "Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma",
abstract = "Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) represent indolent malignancies characterized by multiple episodes of relapse. Therapy has centered on agents that largely target the B-cell receptor pathway. Duvelisib is a second-generation oral inhibitor of phosphoinositide-3 kinase, downstream of the B-cell receptor pathway, approved in the United States for relapsed CLL/SLL and FL. Duvelisib represents a highly active agent, and ongoing investigations, including fixed-duration drug combinations and alternative dosing schedules, are aimed at reducing immune-mediated toxicities.",
author = "Krish Patel and Danilov, {Alexey V.} and Pagel, {John M.}",
note = "Funding Information: Conflict-of-interest disclosure: K.P. has been a consultant for Astra Zeneca, Pharmacyclics, Janssen, Genentech, Celgene, Sunesis, and Verastem. A.V.D. has been a consultant for Astra Zeneca, Abbvie, Teva Oncology, Verastem, Gilead Sciences, Genentech, TG Therapeutics, Celgene, Curis, Janssen, Pharmacyclics, and Seattle Genetics and has received research funding from Aptose Biosciences, Verastem, Astra Zeneca, Gilead Sciences, Takeda, Genentech, Bayer, and Bristol-Meyers Squibb. J.M.P. has been a consultant for Gilead Sciences, Pharmacyclics, TG Therapeutics, and Astra Zeneca. Funding Information: A.V.D. is a Leukemia & Lymphoma Society Scholar in Clinical Research. Publisher Copyright: {\textcopyright} 2019 by The American Society of Hematology",
year = "2019",
doi = "10.1182/blood.2019001795",
language = "English (US)",
volume = "134",
pages = "1573--1577",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "19",
}